Moleculin Net Income Per Employee Trend from 2010 to 2022

MBRX
 Stock
  

USD 1.80  0.03  1.69%   

Moleculin Biotech Net Income Per Employee yearly trend continues to be fairly stable with very little volatility. Net Income Per Employee will likely drop to -1,008,752 in 2022. . Moleculin Biotech Interest Expense is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Interest Expense of 38,700 in 2021. Weighted Average Shares is likely to rise to about 29 M in 2022, whereas Consolidated Income is likely to drop (16.3 M) in 2022.
  
Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin main balance sheet or income statement drivers, such as Interest Expense of 39.7 K, Operating Expenses of 18.6 M or Research and Development Expense of 11.6 M, as well as many exotic indicators such as Total Assets Per Share of 3.74, Quick Ratio of 18.85 or Net Current Assets as percentage of Total Assets of 88.37. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules. It can also supplement various Moleculin Biotech Technical models . Additionally, see the analysis of Moleculin Biotech Correlation against competitors.

Moleculin Net Income Per Employee Breakdown

Showing smoothed Net Income Per Employee of Moleculin Biotech CS with missing and latest data points interpolated. Moleculin Biotech's Net Income Per Employee historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.
Net Income Per Employee10 Years Trend
Decreasing
Slightly volatile
   Net Income Per Employee   
Share
       Timeline  

Moleculin Net Income Per Employee Regression Statistics

Arithmetic Mean(631,641)
Coefficient Of Variation(62.22)
Mean Deviation 352,789
Median(652,606)
Standard Deviation 393,015
Range 976,172
R-Value(0.85)
R-Squared 0.72
Significance 0.00022421
Slope(85,894)

Moleculin Net Income Per Employee History

2016-652.6 K
2017-1.2 M
2018-913.5 K
2019-825.3 K
2020-1.2 M
2021-934.9 K
2022-1 M

About Moleculin Biotech Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Moleculin Biotech income statement, its balance sheet, and the statement of cash flows. Moleculin Biotech investors use historical funamental indicators, such as Moleculin Biotech's Net Income Per Employee, to determine how well the company is positioned to perform in the future. Although Moleculin Biotech investors may use each financial statement separately, they are all related. The changes in Moleculin Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moleculin Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Moleculin Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Net Income Per Employee-934.9 K-1 M
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moleculin Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moleculin Biotech's short interest history, or implied volatility extrapolated from Moleculin Biotech options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Moleculin Biotech Correlation against competitors. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
50.6 M
Return On Assets
-0.19
Return On Equity
-0.28
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.